Every material Form 8-K Amphstar Pharmaceuticals filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Amphastar reported third-quarter 2025 net revenues of $191.8 million, roughly flat from $191.2 million a year earlier. GAAP diluted EPS fell to $0.37 from $0.78, and the company said general and administrative expenses rose mainly because of a $23.1 million litigation provision. Adjusted non-GAAP diluted EPS was $0.93, compared with $0.96 a year earlier.
Net revenues were $191.8 million, up $626 thousand (0%) from $191.2 million in the third quarter of 2024.
GAAP net income was $17.4 million, down from $40.4 million; GAAP diluted EPS was $0.37 versus $0.78.
Adjusted non-GAAP diluted EPS was $0.93 versus $0.96; the adjustments include a $23.1 million litigation provision.
BAQSIMI sales rose 33% to $53.6 million, while glucagon sales fell 49% to $13.6 million.
Amphastar entered a Distribution Agreement effective October 21, 2025, appointing Nanjing Chengong Pharmaceutical as exclusive distributor of BAQSIMI in Mainland China, Taiwan, Hong Kong, and Macau. The filing says the deal's total revenue to Amphastar cannot be determined yet, because per-unit net revenues may vary, and it is a related party transaction with a company controlled by the CEO and Chairman's family.
Agreement effective October 21, 2025, with a ten-year term; either party may terminate without cause after the fourth Contract Year.
Chengong must obtain regulatory approvals in the Region, perform post-marketing clinical trials, and meet minimum purchase amounts per contract year.
Amphastar and Chengong will share profits on earnings above a floor price per unit, based on Chengong's per-unit net revenue.
Dr. Jack Zhang and Dr. Mary Luo, with certain family members, own a majority of Hanxin, Chengong's parent. The independent Audit Committee approved the agreement.
Amphastar Pharmaceuticals entered a three-year contract research agreement on September 15, 2025 with Nanjing Hanxin Pharmaceutical Technology, a company majority-owned by the CEO, COO and Chairman's family. Hanxin will develop cell banks the company will own and use for its product candidate AMP-107, with total cost not expected to exceed about $2.8 million. The deal is with a related party, and the independent Audit Committee approved it.
Agreement effective September 15, 2025, with a term of three years
Total cost to Amphastar not to exceed approximately $2.8 million, paid in Chinese yuan and adjusted for exchange rates
Approximately $0.3 million payable to Hanxin on the Effective Date
Dr. Jack Zhang and Dr. Mary Luo and family members own a majority of Hanxin; independent Audit Committee approved the deal
On August 8, 2025, Amphastar entered into an exclusive license agreement with Nanjing Anji Biotechnology for three peptide-based products in the United States and Canada, and announced it on August 12, 2025. Amphastar paid $0.75 million in earnest money and a $5.25 million upfront payment, with further development and sales milestone payments of up to $42 million and $225 million, contingent on achieving those milestones. The filing ties the deal to Amphastar's pipeline expansion, but the payments depend on future milestones and commercial results.
Agreement signed August 8, 2025; covers three identified peptide products in the US and Canada.
Upfront costs: $0.75 million earnest money and $5.25 million upfront payment to Anji.
Potential payments: up to $42 million in development milestones and up to $225 million in sales milestones.
Royalties owed by Amphastar are capped at $22.5 million per calendar year and $60 million accumulated per product.
Amphastar reported second-quarter 2025 results on August 7, 2025. Net revenues fell 4% to $174.4 million, and GAAP net income declined to $31.0 million, or $0.64 per diluted share, from $0.73 a year earlier. Growth in BAQSIMI sales was offset by lower glucagon and epinephrine sales, and the board increased its share buyback program by $50 million.
Net revenues were $174.4 million versus $182.4 million a year earlier, down 4%.
GAAP diluted EPS was $0.64 versus $0.73; adjusted non-GAAP diluted EPS was $0.85 versus $0.94.
BAQSIMI product revenues rose 51% to $46.7 million; epinephrine revenues fell 42% and glucagon fell 25%.
On August 5, 2025, the board authorized a $50 million increase to the share buyback program.
Amphastar Pharmaceuticals appointed David Gaugh as a Class I director on July 18, 2025, increasing the board from ten to eleven authorized seats. The board determined he is independent under Nasdaq listing standards, and he was not assigned to any committees at this time.
Board approved increase from 10 to 11 authorized directors on July 18, 2025
David Gaugh appointed Class I director, term runs to the 2026 annual meeting, effective immediately
Initial compensation: 50% restricted stock units and 50% stock options, aggregate grant date fair value of $260,000, vesting on first anniversary
Amphastar Pharmaceuticals reported first-quarter 2025 results for the three months ended March 31, 2025, with net revenues of $170.5 million, down 1% from $171.8 million a year earlier. GAAP net income fell to $25.3 million, or $0.51 per diluted share, from $43.2 million, or $0.81 per share, in the prior-year quarter. Lower glucagon and epinephrine sales and higher operating expenses offset growth in BAQSIMI, so shareholders saw lower revenue and profit compared with the prior-year quarter.
Net revenues were $170.5 million, down 1% from $171.8 million; BAQSIMI product revenue rose 177% to $38.4 million.
GAAP net income was $25.3 million, or $0.51 per diluted share, versus $43.2 million, or $0.81, a year earlier.
Adjusted non-GAAP net income was $36.9 million, or $0.74 per diluted share, versus $55.3 million, or $1.04, in the prior-year quarter.
Gross margin was 50.0% versus 52.4% a year earlier; research and development expenses rose to $20.1 million from $17.0 million.
Amphastar Pharmaceuticals reported fourth-quarter and full-year 2024 results on February 27, 2025. Net revenues rose 5% in the quarter and 14% for the year, and GAAP diluted EPS increased from the prior-year periods, though fourth-quarter gross margin fell to 46.5% from 54.0%.
Q4 net revenues were $186.5 million, up from $178.1 million; GAAP diluted EPS was $0.74 versus $0.68 and adjusted non-GAAP diluted EPS was $0.92 versus $0.88.
Full-year net revenues were $732.0 million, up from $644.4 million; GAAP diluted EPS was $3.06 versus $2.60.
Q4 gross margin was 46.5% versus 54.0%, mainly due to lower other revenues after the Lilly Transition Service Agreement with Lilly expired in Q4 2024; BAQSIMI product revenues were $41.8 million in the quarter.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Amphstar Pharmaceuticals filing is on SEC EDGAR ↗. 8-K briefs of other companies →